 |
22 Diseases |  |
6 Trials |
|
6 Trials |  |
188 News |  |
| «123 |
- ||||||||| azeliragon (TTP488) / Cantex Pharma
Enrollment change, Trial completion date, Trial suspension, Trial primary completion date: 2-Year Extension Study of Azeliragon in Subjects With Alzheimer's Disease (STEADFAST Extension) (clinicaltrials.gov) - May 3, 2018
P3, N=298, Suspended, Sponsor: vTv Therapeutics
N=640 --> 298 | Trial completion date: Nov 2020 --> Jun 2018 | Enrolling by invitation --> Suspended | Trial primary completion date: Nov 2020 --> May 2018
- ||||| azeliragon (TTP488) / Cantex Pharma
Enrollment closed: STEADFAST: Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease (clinicaltrials.gov) - Jun 1, 2017
P3, N=800, Active, not recruiting, Sponsor: vTv Therapeutics
N=640 --> 298 | Trial completion date: Nov 2020 --> Jun 2018 | Enrolling by invitation --> Suspended | Trial primary completion date: Nov 2020 --> May 2018 Recruiting --> Active, not recruiting
- |||||| azeliragon (TTP488) / Cantex Pharma
Enrollment open: 2-Year Extension Study of Azeliragon in Subjects With Alzheimer's Disease (STEADFAST Extension) (clinicaltrials.gov) - Jan 4, 2017
P3, N=640, Enrolling by invitation, Sponsor: vTv Therapeutics
Recruiting --> Active, not recruiting Not yet recruiting --> Enrolling by invitation
- |||| azeliragon (TTP488) / Cantex Pharma
Trial primary completion date: STEADFAST: Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease (clinicaltrials.gov) - Nov 18, 2016
P3, N=800, Recruiting, Sponsor: vTv Therapeutics
Not yet recruiting --> Enrolling by invitation Trial primary completion date: Mar 2018 --> Nov 2018
- |||| azeliragon (TTP488) / Cantex Pharma
Trial primary completion date: 2-Year Extension Study of Azeliragon in Subjects With Alzheimer's Disease (STEADFAST Extension) (clinicaltrials.gov) - Nov 18, 2016
P3, N=640, Not yet recruiting, Sponsor: vTv Therapeutics
Trial primary completion date: Mar 2018 --> Nov 2018 Trial primary completion date: Jun 2019 --> Nov 2020
- |||||||||| azeliragon (TTP488) / Cantex Pharma
New P3 trial: 2-Year Extension Study of Azeliragon in Subjects With Alzheimer's Disease (STEADFAST Extension) (clinicaltrials.gov) - Sep 27, 2016
P3, N=640, Not yet recruiting, Sponsor: vTv Therapeutics
- | azeliragon (TTP488) / Cantex Pharma
Enrollment open: STEADFAST: Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease (clinicaltrials.gov) - Apr 29, 2015
P3, N=800, Recruiting, Sponsor: TransTech Pharma, LLC.
Trial primary completion date: Jun 2019 --> Nov 2020 Not yet recruiting --> Recruiting
- | azeliragon (TTP488) / Cantex Pharma
Trial initiation date, Trial primary completion date: STEADFAST: Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease (clinicaltrials.gov) - Apr 14, 2015
P3, N=800, Not yet recruiting, Sponsor: TransTech Pharma, LLC.
Not yet recruiting --> Recruiting Initiation date: Dec 2014 --> Apr 2015 | Trial primary completion date: Jul 2017 --> Mar 2018
- |||| azeliragon (TTP488) / Cantex Pharma
Trial primary completion date: STEADFAST: Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease (clinicaltrials.gov) - Jul 4, 2014
P3, N=800, Not yet recruiting, Sponsor: TransTech Pharma
Initiation date: Dec 2014 --> Apr 2015 | Trial primary completion date: Jul 2017 --> Mar 2018 Trial primary completion date: Mar 2017 --> Jul 2017
- ||||| azeliragon (TTP488) / Cantex Pharma
Trial initiation date, Trial primary completion date: STEADFAST: Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease (clinicaltrials.gov) - Jul 4, 2014
P3, N=800, Not yet recruiting, Sponsor: TransTech Pharma
Trial primary completion date: Mar 2017 --> Jul 2017 Initiation date: Jun 2014 --> Dec 2014 | Trial primary completion date: Mar 2017 --> Jul 2017
- |||||||||| azeliragon (TTP488) / Cantex Pharma
New P3 trial: STEADFAST: Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease (clinicaltrials.gov) - Mar 4, 2014
P3, N=800, Not yet recruiting, Sponsor: TransTech Pharma